O
OTR Therapeutics
Accelerating preclinical assets into differentiated clinical therapies
About OTR Therapeutics
OTR Therapeutics is a biotechnology firm founded in March 2025 by Dr. Zhui Chen, Dr. Shannon Chuai, and Dr. Yuan Shi. The company operates on a model that combines in-house research and development with the strategic acquisition of external innovations. Its operational hub is located in Shanghai. OTR Therapeutics focuses on developing therapies for diseases with significant unmet needs, particularly in oncology, immunology, inflammation, and cardiometabolic conditions.
The company's business model is designed for capital efficiency, aiming to accelerate the development of innovative drugs. This approach involves identifying and acquiring promising preclinical and early-clinical assets to move them into global clinical development. In June 2025, OTR Therapeutics announced it had secured $100 million in a Series A financing round. The funding was backed by investors including True Light Capital, LAV, Pfizer Ventures, and Sirona Capital. These funds are intended to advance the company's pipeline and expand its R&D capabilities. In line with its strategy, the company also acquired a preclinical program with potential for treating neurological diseases.
The founding team brings extensive experience from the biotechnology and pharmaceutical sectors. CEO and Founder, Dr. Zhui Chen, previously co-founded Abbisko Therapeutics and held senior roles at Johnson & Johnson's Shanghai Innovation Center. Co-founder and COO, Dr. Shannon Chuai, has over 20 years of experience in pharmaceuticals and diagnostics, having co-founded Burning Rock Biotech. Dr. Yuan Shi, Co-founder and CSO, has a background in drug discovery and clinical portfolio management from his time at Eli Lilly and co-founding INF Technology.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2025 | $100M | $400M | Pfizer Ventures · LAV · Sirona Capital · True Light | ↗ |
Growth signals
Latest recorded traffic for OTR Therapeutics is 930 monthly website visits, up 78.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OTR Therapeutics in its local ecosystem
The OTR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- PVPfizer Ventures
- LALAV
- SCSirona Capital
True Light
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OTR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OTR Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









